Pilot & Feasibility
Protocols & Methods
Reagents & Resources
Tissues & Samples
IMPC / KOMP Data
Pilot & Feasibility
Redefining DM by Agnostic Kidney Interrogation: A Pilot Grant
Diabetes results in a range of kidney abnormalities that involves many cell types as diverse as glomerular mesangial cells and renal tubules, but it remains to be seen whether all cellular targets of diabetes in the kidney have yet been identified. Nonetheless, pathologic staging has been instituted. The disease is staged in pathological Classes I-IV, yet whether these classes account for all affected cells and whether the classes are truly discrete or represent a continuum of disease also remains to be seen. While renal biopsy provides some answers, some diabetic findings, even the pathognomonic Kimmelstiel-Wilson lesion can also be found in non-diabetic patients, raising questions concerning not only diagnosis but also pathogenesis. Most troubling has been the problem of diagnosis and prognostication upon patient encounter. This is because our field has serious limitations in the diagnosis of both tubular and glomerular diseases, and surely new tools that are more sensitive and specific than sCr and uProtein are required. Our team has contributed to attempts to rethink the field of AKI by identifying and studying the biology and clinical utility of urinary NGAL which is dramatically and rapidly upregulated by kidney damage but not when sCr was elevated because of volume-dependent changes, hence distinguishing different AKI stimuli. Using similar approaches, we have recently identified loss of a cytokine inhibitor in the glomerular disease CFH deficiency. In this pilot, we wish to take related approaches to understand the protean forms of diabetes as we did for AKI and CFH. However, tools that were applicable to mouse models are not useful in human frozen kidney biopsy samples. To apply gene discovery in this case requires techniques that are scaled to very small amounts of tissues and withstand freezing. In addition, because many cell types are targeted by diabetes, analysis should be done at a single cell level in order not to confound data by aggregation. Working with a leading bioengineer, Sims, mathematician, Rabadan, and statistical geneticist, Kiryluk, we have developed the methodology to interrogate frozen biopsies by rapid isolation of nuclei coupled to single nuclear sequencing. Preliminary results from normal biopsies show feasibility and now we will obtain preliminary data from diabetic biopsies. We will investigate Normal, Diabetic Nephropathy, Diabetic Nodular Nephropathy and Non-Diabetic Nodular Nephropathy. The deliverables are successful sn-RNAseq demonstrating unique cohorts of genes in 12 samples, preliminary topological data analysis and identification of secreted proteins.
No funding program application progress reports found.
No uploaded documents found.
No publications found.
No uploaded documents found.
No protocols found.
The DiaComp Steering Committee is the governing body of the consortium. The principle function of this committee is to guide the scientific direction of the consortium. This is accomplished by creating various subcommittees necessary to advance the scientific goals and providing guidance to the broader complications research community. Policies for the consortium are developed through consultation with the
External Evaluation Committee
The DiaComp Nephropathy Committee has the principal function of furthering the mission of the consortium with regard to diabetic kidney disease.
Curation Flag Information
New comment to be added:
No experiments found.
No strains found.
No models found.
Welcome to the DiaComp Login / Account Request Page.
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an external advisor to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
There was a problem with the page:
Safari Browser Detected...
We strive to make the DiaComp site compatable with as many browsers as possible, but some of our third party tools don't work with the Safari browser.
In order to explore this site we highly recommend using the most recent versions of the following browsers:
© 2018 DiaComp.org
All rights reserved
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!